… -based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study: protocol
for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. …

… Numerous neurodegenerative conditions, such as Alzheimer’s, Huntington’s, Parkinson’s,
amyotrophic lateral sclerosis, and glioblastoma multiform are now becoming significant …

… There are currently only two FDA approved drugs for its treatment, and both offer mild …
treatment. dl-Potassium 2-(1-Hydroxypentyl)-benzoate (dlPHPB) is a novel drug for the treatment …

… trauma is considered a potential risk factor of amyotrophic lateral sclerosis (ALS), but their
… targeted treatment regimens and make prophylactic strategies for ALS in traumatic patients. …

… and also a clinically available medication for patients with liver … diseases, including amyotrophic
lateral sclerosis (ALS). … a potential therapeutic candidate for ALS because of its multiple …

… therapy approach with the potential to impact the large majority of ALS patients, and to be
quickly translated from bench to bedside. … Once the optimal dosing and length of treatment has …

… the pathogenesis of sporadic Amyotrophic Lateral Sclerosis (sALS) is … Amyotrophic Lateral
Sclerosis (ALS) is a progressive … primary therapy for ALS with a very limited number of drugs …

… This review provides a comprehensive analysis of the potential of antioxidant therapy,
challenges in their clinical translation, and the role nanoparticles/drug delivery systems could play …

Background: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder which affects
the motor neurons. Growing evidence suggests that ALS may impact the metabolic system, …

… amyotrophic lateral sclerosis epitomize a class of insidious and relentless neurological
conditions that are difficult to cure. Conventional therapeutic … in the pharmacological treatment of …